Research programme: hyperparathyroidism therapy - ProStrakan

Drug Profile

Research programme: hyperparathyroidism therapy - ProStrakan

Alternative Names: PSK 1594

Latest Information Update: 18 Sep 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ProStrakan
  • Class
  • Mechanism of Action Calcium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperparathyroidism

Most Recent Events

  • 22 Dec 2006 Galapagos NV acquires ProStrakan's drug discovery unit
  • 22 Dec 2006 Discontinued - Preclinical for Hyperparathyroidism in Europe (unspecified route)
  • 17 Aug 2006 Preclinical trials in Hyperparathyroidism in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top